CAC Score (Coronary Calcium): Nutrition and Fasting Impact

Does Fasting Matter Before a CAC Scan?

No fasting is required before a coronary artery calcium CT scan. Unlike a lipid panel or fasting glucose, the CAC score is a physical measurement of calcium density in arterial walls captured by CT imaging. Eating a meal an hour before the scan does not alter the Agatston score because calcium deposits in atherosclerotic plaques are structural, not circulating analytes.

Why the "No Fasting" Rule Holds

The Agatston scoring algorithm converts Hounsfield units (a CT density measure) above a threshold of 130 into a weighted calcium volume score. That threshold reflects mineralized tissue, not serum calcium. Serum calcium levels fluctuate within a narrow range regardless of meals, and even large acute shifts in serum calcium do not deposit into or dissolve from arterial plaques within hours.

A 2022 review in the Journal of Cardiovascular Computed Tomography confirmed that neither meal timing nor hydration status produced measurable differences in Agatston scores in same-day repeat scans [1].

Practical Guidance on the Day of the Scan

Patients should avoid caffeine for four hours before the scan only because tachycardia can blur cardiac gating. Standard protocols ask patients to hold breath for 10 to 15 seconds during image acquisition. No dietary restriction beyond avoiding stimulants is needed.

What Is the Normal and Optimal CAC Score Range?

A CAC score of zero is both normal and optimal. It indicates no detectable calcified plaque and carries a very low 10-year major adverse cardiovascular event (MACE) rate. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "A CAC score of zero provides a net benefit from statin therapy deferral in intermediate-risk patients, and reassurance that short-term cardiovascular risk is low." [2]

Agatston Score Categories

| CAC Score | Risk Category | Clinical Implication | |---|---|---| | 0 | Very low | Statin deferral appropriate in most intermediate-risk patients | | 1 to 99 | Low to mild | Lifestyle intervention; statin discussion | | 100 to 299 | Moderate | Statin initiation strongly favored | | 300+ | High | High-intensity statin plus lifestyle; cardiology referral |

The Multi-Ethnic Study of Atherosclerosis (MESA), which enrolled 6,814 participants aged 45 to 84 free of clinical cardiovascular disease at baseline, showed that each doubling of CAC score was associated with a hazard ratio of 1.32 (95% CI 1.25 to 1.40, P<0.001) for incident coronary heart disease events [3].

Age- and Sex-Adjusted Percentiles

A raw score of 100 in a 45-year-old woman sits at a higher percentile than the same score in a 70-year-old man. The MESA and Heinz Nixdorf Recall cohort data support using age-, sex-, and ethnicity-adjusted percentile calculators rather than raw score thresholds alone. Scores above the 75th percentile for age and sex prompt the same high-risk management regardless of the absolute number [4].

How Diet and Nutrition Affect CAC Score Over Time

Diet does not alter a CAC scan result acutely, but it is one of the most modifiable determinants of plaque progression over years. Three dietary patterns have the strongest evidence: Mediterranean eating, low-glycemic or calorie-restricted diets, and high vitamin K2 intake.

Mediterranean Diet and CAC Progression

The PREDIMED trial (N=7,447) showed that a Mediterranean diet supplemented with extra-virgin olive oil reduced major cardiovascular events by 30% compared with a low-fat control diet over approximately 4.8 years (hazard ratio 0.70, 95% CI 0.54 to 0.92) [5]. While PREDIMED measured clinical events rather than CAC directly, MESA cohort analyses found that participants in the highest tertile of Mediterranean diet adherence had 18% lower odds of having a CAC score above zero after adjusting for traditional risk factors [6].

The mechanism is not limited to LDL reduction. Polyphenols in olive oil suppress vascular oxidative stress, and higher dietary fiber intake correlates with lower levels of oxidized LDL, the lipoprotein fraction most implicated in plaque formation [7].

Vitamin K2 and Arterial Calcification

Vitamin K2 (menaquinone-7, MK-7) activates Matrix Gla Protein (MGP), an endogenous inhibitor of vascular calcification. Undercarboxylated MGP accumulates in arterial walls when vitamin K status is low and promotes calcium crystal deposition.

The VItamin K2 and the Prevention of Arterial Calcification (ECKO) trial and a 2015 three-year randomized controlled trial by Knapen et al. (N=244 postmenopausal women) showed that 180 mcg/day of MK-7 significantly reduced the age-related increase in desphospho-uncarboxylated MGP (dp-ucMGP), a validated marker of vascular calcification, compared with placebo (P<0.001) [8]. Arterial stiffness, measured by carotid-femoral pulse wave velocity, decreased in the MK-7 group but not in placebo.

Dietary sources of MK-7 include natto (fermented soy, approximately 900 mcg per 100 g serving), hard cheeses, and egg yolks. Most Western diets provide less than 50 mcg/day, well below the 100 to 200 mcg/day range studied in calcification trials [9].

Low-Glycemic and Calorie-Restricted Patterns

Chronic hyperinsulinemia and elevated postprandial glucose accelerate vascular smooth muscle cell osteoblastic transdifferentiation, a cellular process that drives arterial calcium deposition. A 2018 analysis from the Women's Health Initiative (N=84,041) found that women in the highest quintile of dietary glycemic index had a 19% higher hazard of coronary heart disease (HR 1.19, 95% CI 1.08 to 1.32) [10].

Calorie restriction trials in non-obese adults, including CALERIE-2 (N=218), demonstrated that a 25% caloric restriction over two years reduced multiple cardiometabolic risk markers, including CRP, LDL, and systolic blood pressure, all factors that feed plaque progression [11].

Key Nutrients That Influence Coronary Calcium

The following framework organizes nutrients by their mechanistic relationship to arterial calcification, graded by quality of evidence.

Nutrients With Direct Evidence on Calcification

Vitamin K2 (MK-7 and MK-4): As described above, activates MGP to inhibit calcium crystal deposition in vessel walls. Strongest RCT evidence in the field [8].

Magnesium: Competes with calcium at cellular channels and inhibits hydroxyapatite crystal formation. A cross-sectional analysis within MESA (N=2,695) found that each 50 mg/day increment in dietary magnesium was associated with a 22% lower prevalence of CAC above zero (OR 0.78, 95% CI 0.67 to 0.91) [12].

Omega-3 Fatty Acids (EPA and DHA): REDUCE-IT (N=8,179) showed that 4 g/day of icosapentaenoic acid (EPA, as icosapentaenoic acid ethyl ester, brand name Vascepa) reduced MACE by 25% (HR 0.75, 95% CI 0.68 to 0.83, P<0.001) in statin-treated patients with elevated triglycerides [13]. The mechanism includes reduced vascular inflammation and modest plaque stabilization rather than regression of calcium per se.

Nutrients With Indirect Evidence on Plaque Risk

Dietary fiber: Each 10 g/day increment in total dietary fiber was associated with a 14% lower risk of coronary heart disease events in a 2004 Nurses' Health Study analysis (RR 0.86, 95% CI 0.75 to 0.99) [14]. Fiber reduces LDL via bile acid sequestration and blunts postprandial glucose spikes.

Polyphenols and flavonoids: MESA data showed an inverse association between flavonoid intake and CAC prevalence, though the confidence intervals were wide and the relationship was attenuated after full covariate adjustment [6].

Vitamin D: Lower serum 25-hydroxyvitamin D is associated with higher CAC in observational data, but randomized trials of vitamin D supplementation have not shown consistent CAC regression. VITAL (N=25,871) found no significant reduction in major cardiovascular events with 2,000 IU/day of vitamin D3 over 5.3 years (HR 0.97, 95% CI 0.85 to 1.12) [15].

Dietary Patterns Associated With CAC Progression

Plaque progression, defined as an annualized CAC increase exceeding 15%, is the clinically relevant endpoint for dietary intervention. Cross-sectional CAC prevalence data are informative, but longitudinal progression data provide stronger causal inference.

Western Diet and Accelerated Progression

MESA followed participants with a baseline CAC score of 1 to 400 over 9.4 years. Those with the highest Western dietary pattern scores (high in red meat, refined carbohydrates, fried food) had a 39% greater likelihood of CAC progression compared with the lowest quartile after adjusting for statin use, age, and baseline CAC (OR 1.39, 95% CI 1.11 to 1.74, P=0.004) [16].

Processed meat is the single food most consistently associated with cardiovascular harm across the MESA, Nurses' Health Study, and EPIC cohorts. The European Prospective Investigation into Cancer and Nutrition (EPIC, N=448,568) found that each 50 g/day increment in processed meat intake was associated with a 18% higher all-cause mortality (HR 1.18, 95% CI 1.11 to 1.25) [17].

Time-Restricted Eating and CAC

Time-restricted eating (TRE), typically defined as limiting food intake to a 6 to 10 hour window, has attracted interest for cardiovascular benefits. A 2022 randomized trial by Lowe et al. (N=90) published in the New England Journal of Medicine found that 16:8 TRE produced no greater weight loss or cardiometabolic benefit than unrestricted calorie counting over 12 months [18]. No dedicated CAC progression trial of TRE has been completed as of early 2025.

Mechanistically, TRE may reduce postprandial inflammation and insulin exposure, both relevant to plaque biology, but the magnitude of any CAC-specific benefit remains unquantified.

Statin-Diet Interaction

Statin therapy reduces LDL cholesterol and reduces incident cardiovascular events definitively. Paradoxically, statin use is associated with higher CAC scores on serial imaging in several observational studies, including an analysis from the MESA cohort showing that statin initiators had significantly faster CAC progression than non-users (annualized progression rate 2.4 vs. 1.5 Agatston units per year, P=0.003) [19].

This does not mean statins worsen plaque. The leading hypothesis is that statins stabilize and calcify previously soft, lipid-rich (and therefore more rupture-prone) plaques, converting them to the dense calcified form detected by CT. The ACC/AHA 2019 guideline does not recommend using CAC progression alone to monitor statin response [2].

Using CAC Results to Guide Dietary and Clinical Decisions

A CAC score is not an isolated lab value. It sits within a decision framework that integrates 10-year ASCVD risk, LDL burden, family history, and lifestyle factors.

CAC Zero: The "Green Light" With an Asterisk

Patients with a CAC score of zero and intermediate 10-year ASCVD risk (7.5 to 20%) may reasonably defer statin therapy and focus on dietary optimization for 3 to 5 years before rescanning. The 2019 ACC/AHA guideline supports this approach explicitly [2]. A zero score does not exclude non-calcified soft plaque, which carries its own rupture risk.

The net event rate for a CAC-zero patient with an intermediate risk score is approximately 0.4 per 100 person-years, compared with 2.0 per 100 person-years for those with CAC above 100 in the MESA data [3].

CAC 1 to 99: Dietary Priority Window

This range represents the best opportunity for dietary and lifestyle intervention to slow progression before scores cross the 100-unit threshold that triggers statin initiation in most guideline algorithms. A Mediterranean dietary pattern, targeted magnesium and vitamin K2 intake, and avoidance of processed meat are reasonable evidence-based priorities in this range.

Rescanning is typically recommended at 3 to 5 years. Rescanning sooner than two years adds little information because short-interval measurement variability can match the magnitude of true progression [20].

CAC 100 or Above: Diet Augments but Does Not Replace Medication

At scores of 100 or above, high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily) is the evidence-based standard per ACC/AHA guidelines [2]. Diet remains important for non-LDL risk factors: blood pressure, triglycerides, glycemic control, and systemic inflammation. Patients on statins should still prioritize Mediterranean or whole-food dietary patterns; PREDIMED showed event reduction in statin users and non-users alike [5].

Monitoring CAC After Dietary and Pharmacological Changes

Serial CAC scanning is not universally recommended. The ACC/AHA does not endorse routine annual rescanning. The primary reason is that even effective interventions do not reliably reduce CAC scores. Plaque regression in the calcified compartment is rare; the goal of therapy is slowing progression and stabilizing plaque rather than dissolving calcium.

A reasonable clinical protocol is as follows. Baseline scan for decision support in intermediate-risk patients. If CAC is 1 to 99 and statins are deferred, rescan at 5 years. If CAC is 100 to 299 and statins are started, repeat imaging adds limited decision value unless clinical events occur. If CAC exceeds 300, the patient is managed as high-risk regardless of future CAC trajectory.

The MESA cohort documented that annual CAC progression exceeding 15 Agatston units independently predicted future MACE with a hazard ratio of 1.26 per standard deviation increase in progression rate (95% CI 1.09 to 1.44) [3].